

## Connectome-derived Biomarkers

NICARA™ for clinical trials



## Biomarkers for Clinical Aging Studies - Requirements



Biomarkers should be easy to obtain



Biomarkers should detect and quantify brain changes preceding gross atrophy



Biomarkers should respond to treatment



Biomarkers should serve as outcome marker in clinical trials



Biomarkers should be reproducible and reliable



Do your biomarkers fulfill all these requirements?



### Quality Prediction of Biomarkers in Aging Studies – A Real Challenge

#### Volumetric Measurements

Widely used, but with only moderate prediction quality

# **Cognitive Testing**

Necessary, but time consuming and expensive Sophisticated markers from PET-MRI, fMRI & DTI

Can greatly enhance prediction quality



## Connectome-derived Biomarkers for Aging Studies?

The CONNECTOME

can be extracted from tractography (DTI) or from time series correlations (fMRI, MEG, EEG).

The CONNECTOME is directly affected by neurodegeneration. Alzheimer's disease (AD) as a disconnection syndrome.


CONNECTOME alterations correlate with cognitive impairments.

Anti-dementive treatment was reported to have a protective effect on the structural and functional CONNECTOME.

However, extracting and analyzing the connectome requires expert knowledge in neuroimaging and expensive hardware.



## Our Solution: NICARA™



- NICARA provides fully automated processing routines for structural and functional connectome extraction
- > NICARA allows fully integrated study management and catalog functions for connectome data
- > NICARA enables visualization, exploration and comparisons of multimodal connectome information and morphometry.



## NICARA Offers You Many Advantages



...precise patient stratification

...better monitoring of treatment outcome





.. expert knowledge

...hardware resources



- > More precise patient characterization by earlier detection of, e.g., accelerated neurodegeneration
- > Better monitoring of treatment outcome by connectome assessments before and after treatment
- > Create more predictive biomarkers based on morphometry and connectome changes
- > No neuroimaging knowledge needed
- > Hardware resources provided by Biomax Informatics




## Use Case: NICARA for Alzheimer's Disease (AD)

(as an example for detecting brain changes in Aging, Neurodegeneration and Dementia)





## A preferred DTI Pipeline for AD Connectomes



All pipeline tools executed by NICARA are...

- open source
- validated in hundreds of studies
- suggested as preferred neuroimaging method for AD drug development\*.


\*in Falcon C, et al. Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. Methods Mol Biol. In Biomarkers for Alzheimer's Disease Drug Development edited by Robert Perneczky (2018)






## From Image to Feature Space: Exploring AD Connectomes

## Fiber Density Maps (Image Space)



Reddish: high densities; Blueish: low densities of fibers of a major white matter tract in DTI tractography

## 3D Lattice Graph (Feature Space)



(DTI tractography of a subnetwork)


Bold lines: high fiber densities; Thin lines: low fiber densities

- visualizations (e.g., fiber density maps) give a reliable overview of the patient's connectome.
- representation allows for more precise quantification, multi-modal connectome integration and feasible inter-subject comparability.




## Characterization of AD Patients with Brain Network Comparison

#### **AD Patient**



AD patient: reduced densities

#### **Matched Control**




Healthy matched control: stronger and more connections

NICARA detects differences in the connectome of AD patients and healthy matched controls of any fiber tract\* or functional brain network.

\* here: Cingulum fiber tract




## **Easy to Interpret Patient Report**



NICARA delivers an overview of the patient's brain connectivity in comparison to averaged connectivity of matched controls and standard distribution.



## Effects of Treatment with Longitudinal Assessments



Changes in brain connectivity from cold to warm colors

Percentage changes (x-axis) of connections (y-axis) (sorted from strongest increase to strongest decrease)

NICARA helps
 assess
 longitudinal
 changes in brain
 connectivity
 before and after
 treatment.




## Morphometry Reports with NICARA



> NICARA
delivers
manifold reports
on the
quantification of
morphometry of
the patient's
brain regions.




## Connectivity Combined with Surface Based Morphometry



between surface based morphometry of brain regions and surface based full brain DTI tractography for a more precise patient characterization in clinical trials.



## NICARA for Clinical Trials at a Glance






## Choose Biomax Informatics as your Preferred Partner

- > We have more than 20 years of experience in knowledge management for the life sciences
- > We have a validated technology through multi-year contracts with reference customers and thousands of users worldwide
- > We have a multidisciplinary team of life science and software experts
- > We have a flexible technology to adapt to your individual needs fast and effectively
- > We are fully GDPR compliant and certified according to ISO 9001 and ISO 27001



### Interested in a DEMO of NICARA?



Register a free demo account at nicara.eu or contact nicara@biomax.com for a free consultation!

